Atrial Fibrillation Circulatory System Arrhythmia
Conditions
Interventions
All participants will receive a medication (Amiodarone) for at least 6 weeks prior to their procedure. Study participants will provide informed consent prior to commencement of the study protocol. The
Sponsors
Imperial College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Atrial fibrillation due to undergo an AF ablation procedure 2. Informed consent 3. Willing to attend follow up for Holter monitoring 4. Suitable for AF ablation procedure under general anaesthetic
Exclusion criteria
Exclusion criteria: 1. Left Ventricular Ejection Fraction 4.8 cm 3. Failed cardio version with sinus rhythm lasting <1 week 4. Any significant co-morbidity precluding general anaesthetic or a contra-indication to ablation 5. Pregnant women 6. Patients with life expectancy less than follow up period 7. Unwillingness to attend follow up HoltersIf 8. Patients who have undergone previous experimental ablation procedures 9. Patients involved in research that could itself be affected by our intervention protocols
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Recurrence of >30 seconds of AF or atrial tachycardia at 1 year as measured on 24 hour Holters at 3, 6, 9, & 12 months post procedure (after a 90-day blanking period) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Acute cessation of ectopy and/or AF with ablation during the procedure (noted during the procedure) Measured using patient records at the end of the study: 2. Repeat ablation for AF/AT after a 90-day blanking period 3. Mortality 4. Any significant complications related to the procedure requiring intervention | — |
Countries
England, United Kingdom
Outcome results
None listed